ZA200704394B - Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection - Google Patents

Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection

Info

Publication number
ZA200704394B
ZA200704394B ZA200704394A ZA200704394A ZA200704394B ZA 200704394 B ZA200704394 B ZA 200704394B ZA 200704394 A ZA200704394 A ZA 200704394A ZA 200704394 A ZA200704394 A ZA 200704394A ZA 200704394 B ZA200704394 B ZA 200704394B
Authority
ZA
South Africa
Prior art keywords
beta
lactamase
compositions
normally
sodium
Prior art date
Application number
ZA200704394A
Other languages
English (en)
Inventor
Chaudhary Manu
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of ZA200704394B publication Critical patent/ZA200704394B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
ZA200704394A 2004-12-02 2007-05-29 Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection ZA200704394B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2411DE2004 2004-12-02

Publications (1)

Publication Number Publication Date
ZA200704394B true ZA200704394B (en) 2008-09-25

Family

ID=35789266

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704394A ZA200704394B (en) 2004-12-02 2007-05-29 Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection

Country Status (23)

Country Link
US (2) US8273732B2 (ru)
EP (1) EP1841432B1 (ru)
JP (1) JP5269415B2 (ru)
KR (2) KR101244362B1 (ru)
CN (1) CN101060846A (ru)
AT (1) ATE476981T1 (ru)
AU (1) AU2005310888B2 (ru)
BR (1) BRPI0517128A (ru)
CY (1) CY1110886T1 (ru)
DE (1) DE602005022939D1 (ru)
DK (1) DK1841432T3 (ru)
ES (1) ES2349301T3 (ru)
HR (1) HRP20100591T1 (ru)
MX (1) MX2007006540A (ru)
NZ (1) NZ555075A (ru)
PL (1) PL1841432T3 (ru)
PT (1) PT1841432E (ru)
RS (1) RS51506B (ru)
RU (1) RU2397768C2 (ru)
SI (1) SI1841432T1 (ru)
UA (1) UA91204C2 (ru)
WO (1) WO2006059344A1 (ru)
ZA (1) ZA200704394B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
WO2010013640A1 (ja) * 2008-07-28 2010-02-04 Yamaguchi Keizo 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
KR20140035376A (ko) * 2011-05-28 2014-03-21 욱크하르트 리미티드 항균제 및 타조박탐을 포함하는 조성물
US9095594B2 (en) * 2011-07-26 2015-08-04 Wockhardt Ltd. Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
GEP20166470B (en) 2012-03-26 2016-04-25 Santen Pharmaceutical Co Ltd Diquafosol-containing eye drop
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CA2886402A1 (en) * 2012-09-27 2014-04-03 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
RU2016136833A (ru) 2014-02-18 2018-03-22 Чилдрен'З Хоспитал Лос Анджелес Композиции и способы для лечения нейтропении
US20170151221A1 (en) * 2014-03-29 2017-06-01 Wockhardt Limited Pharmaceutical compositions comprising cefepime or sulbactam
CA2914314C (en) * 2014-04-03 2021-05-18 Baxter International Incorporated Injection bag and injection preparation assembly
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
US10668079B2 (en) 2016-11-02 2020-06-02 Xiangbei Welman Pharmaceutical Co., Ltd. Composition composed of ceftriaxone sodium and sulbactum sodium
CN106822147B (zh) * 2016-11-03 2021-07-20 湘北威尔曼制药股份有限公司 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
PT1468697E (pt) * 2003-04-14 2008-03-05 Wyeth Corp Composições contendo piperacilina e tazobactam úteis para injecção

Also Published As

Publication number Publication date
AU2005310888A1 (en) 2006-06-08
JP5269415B2 (ja) 2013-08-21
WO2006059344B1 (en) 2006-11-02
EP1841432A1 (en) 2007-10-10
WO2006059344A1 (en) 2006-06-08
CY1110886T1 (el) 2015-06-10
US20100160277A1 (en) 2010-06-24
DK1841432T3 (da) 2010-12-06
KR20070067189A (ko) 2007-06-27
PL1841432T3 (pl) 2011-01-31
UA91204C2 (ru) 2010-07-12
ES2349301T3 (es) 2010-12-29
KR20090101514A (ko) 2009-09-28
EP1841432B1 (en) 2010-08-11
SI1841432T1 (sl) 2011-02-28
HRP20100591T1 (hr) 2010-12-31
RU2007124325A (ru) 2009-01-10
CN101060846A (zh) 2007-10-24
JP2008521884A (ja) 2008-06-26
PT1841432E (pt) 2010-10-25
DE602005022939D1 (de) 2010-09-23
US8273732B2 (en) 2012-09-25
ATE476981T1 (de) 2010-08-15
KR101244362B1 (ko) 2013-03-18
AU2005310888B2 (en) 2011-01-06
US9012442B2 (en) 2015-04-21
RU2397768C2 (ru) 2010-08-27
MX2007006540A (es) 2008-01-31
US20130023512A1 (en) 2013-01-24
RS51506B (en) 2011-06-30
NZ555075A (en) 2011-02-25
BRPI0517128A (pt) 2008-09-30

Similar Documents

Publication Publication Date Title
ZA200704394B (en) Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection
JP7245289B2 (ja) 細菌感染症の処置方法
Martirosov et al. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
US20060189584A1 (en) Pharmaceutical combinations
JP2015147783A (ja) メチルナルトレキソンを含む医薬処方物
WO2007112000A3 (en) Treatment of pain
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
TW200639159A (en) Treatment of pain
CA2597812A1 (en) Parenteral combination therapy for infective conditions with drug resistant bacterium
JP2008540515A (ja) 嚢胞性線維症を含む重症感染症の処置および管理
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
JP2023012538A (ja) 細菌感染症を処置する方法
WO2005092442B1 (en) Method and compositions for treatment of chronic neuropathic pain
Scheinfeld Extensive hidradenitis suppurativa (HS) Hurly stage III disease treated with intravenous (IV) linezolid and meropenem with rapid remission
CN1709263A (zh) 抗菌素组合物
WO2022177968A8 (en) Therapeutic methods
Teng et al. Piperacillin–Tazobactam
EP2979694A1 (en) Succinic acid compounds for use in bacterial infections
JP2017508769A5 (ru)
CO et al. Pascalis Vergidis and Matthew E. Falagas
Vergidis et al. Beta-Lactamase Inhibitors
TW200618812A (en) Compositions containing piperacillin and tazobactam useful for injection